Check handling and unwanted effects.

As of September 2026, FDA’s concerns about some compounded peptides include immune reactions, impurities and limited information from human use. FDA’s concerns about these ingredients ↗

An immune reaction occurs when the body responds to a substance as though it were an invader. Ask what is known about your proposed product, what is unknown and what would make the clinician change the plan.

Include questions about your medicines, allergies, pregnancy plans and breastfeeding. Request an answer for the exact treatment rather than for peptides as a group.

Product guidance checked in September 2026 gives different storage conditions for different peptide medicines; some need refrigeration and others do not. The US health guide for semaglutide injections ↗ FDA’s room-temperature label for tesamorelin ↗

Ask the pharmacist to explain the label, storage conditions and use-by information. Keep those instructions with the medicine. Do not replace them with a general internet chart.

FDA advice checked in September 2026 is to avoid using injectable GLP-1 medicines delivered warm or with too little refrigeration. FDA’s delivery advice ↗

GLP-1 medicines imitate a signal your body makes naturally to help regulate hunger and blood sugar. The delivery advice concerns that group; it is not a storage rule for every peptide.

As of September 2026, reports received by FDA describe unwanted effects possibly linked to dosing mistakes with compounded semaglutide injections. Some reports involved hospital care. FDA’s account of dosing mistakes ↗

If the written directions and what you were told do not agree, contact the prescriber or pharmacist to resolve them. Ask for a corrected written explanation.

Keep a record of the product and who supplied it. Have the way to reach the clinician ready before treatment begins.